Tharimmune, INC 8-K filings

Canton Strategic Holdings, Inc. announced its second quarter 2026 financial results, marking the first operating revenue from its locking service and Super Validator operations, alongside the sale of its legacy biotechnology subsidiary.

Canton Strategic Holdings, Inc. has sold its wholly owned subsidiary, Gravitas Life Sciences, LLC, to Gravitas Collective Corp. for a $3.5 million promissory note and potential milestone payments.

Canton Strategic Holdings, Inc. announced the results of its 2026 annual meeting of stockholders, including the election of directors and ratification of its independent auditor.

Canton Strategic Holdings announced its Board of Directors has authorized a $50 million share repurchase program, signaling confidence in its platform and long-term value.

Canton Strategic Holdings announced full year 2025 financial and operational results, highlighting its new digital asset strategy and strengthened capital position.

Canton Strategic Holdings' Chairman and CEO, Mark Wendland, has been elected to the Board of Directors of the Canton Foundation, reinforcing the company's role in digitizing financial markets.

Tharimmune, Inc. announced the appointment of Angela Radkowski as Chief Operating Officer and the election of CEO Mark Wendland as Chairman of the Board, alongside regaining Nasdaq compliance.

Tharimmune stockholders approved new board members and key equity proposals, reinforcing its digital asset treasury strategy with the Canton Network.

Tharimmune, Inc. announced its approval to operate as a Super Validator on the Canton Network, enhancing its digital asset treasury strategy and network contributions.

Tharimmune, Inc. closed a $55 million underwritten registered direct offering to fund its Canton-centric digital asset treasury strategy and general corporate purposes.

Tharimmune, Inc. announced the pricing of a $55 million registered offering to fund its digital asset treasury strategy and general corporate purposes.

Tharimmune, Inc. received a Nasdaq notification for non-compliance with board independence rules but expects to regain compliance after a special shareholder meeting.

Tharimmune, Inc. announced the appointment of Jacob Asbury as Chief Financial Officer, effective immediately, to lead its digital asset treasury strategy.

Tharimmune, Inc. announced the appointment of Sireesh Appajosyula as interim Chief Financial Officer, effective November 7, 2025, until December 31, 2025.

Tharimmune, Inc. announced the closing of a $545 million private placement to fund its new Canton Coin digital asset treasury strategy and appointed new leadership.

Tharimmune, Inc. completed a private placement raising $545 million and announced significant leadership changes, including a new CEO and President, signaling a strategic focus on digital assets.

Tharimmune, Inc. announced a private placement offering of common stock and pre-funded warrants, including a cryptocurrency-backed option, to fund a new Canton Coin treasury strategy.

Tharimmune, Inc. announced a $540 million private placement to fund a new Canton Coin treasury strategy, positioning itself as a key player in institutional blockchain adoption.

Tharimmune, Inc. amended its Certificate of Incorporation to increase authorized common stock from 250 million to 1 billion shares and establish 10 million preferred shares.

Tharimmune, Inc. stockholders approved proposals to significantly increase authorized common stock and shares reserved for its equity incentive plan, along with authorization for future non-public offerings.

Tharimmune, Inc. announced an amendment making warrants to purchase 3,408,110 shares of common stock immediately exercisable.

Tharimmune's Compensation Committee approved significant salary increases and enhanced change-of-control severance packages for its CEO and Executive Chairman.

Tharimmune, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement, closing the matter with the exchange.

Tharimmune, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement after completing two registered direct offerings totaling approximately $7.05 million.

Tharimmune, Inc. announced a registered direct offering of $5.35 million in common stock and pre-funded warrants to fund working capital.

Tharimmune, Inc. announced a registered direct offering to raise $5.35 million through the sale of common stock.

Tharimmune, Inc. announced the appointment of Nancy Davis, founder of Race to Erase MS and Cure Addiction Now, to its Board of Directors, effective August 4, 2025.

Tharimmune, Inc. has completed a private placement, raising approximately $1.23 million through the issuance of common stock, pre-funded warrants, and common warrants to accredited investors.

Tharimmune, Inc. announced the pricing of a $1.74 million registered direct public offering of common stock and pre-funded warrants, alongside a concurrent private placement of common warrants, to fund working capital and general corporate purposes.

Tharimmune, Inc. reported the immediate resignation of Kelly Anderson from its Board of Directors on June 22, 2025, citing personal reasons.